# New York Licenses Five New Medical Marijuana Companies > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/new-york-medical-marijuana-program-expansion/ > **Published:** 2026-04-11T21:09:20-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:24:44-04:00 > **Clinical Summary:** Explore the new york medical marijuana program expansion with five licensed companies improving patient access and product availability. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AccessPolicy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Patient CareRegulation Why This Matters Market expansion in New York’s [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) program directly affects patient access to regulated products and clinical oversight opportunities. Increased competition among licensed operators typically improves product quality, availability, and pricing for patients with qualifying conditions. Clinical Summary New York has licensed five additional [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) companies, expanding the state’s regulated cannabis market. This regulatory expansion follows the state’s ongoing evolution of its [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) program, which serves patients with specific qualifying conditions including [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), PTSD, and cancer. The addition of new licensed operators increases production capacity and retail access points within the state’s vertically integrated system. Dr. Caplan’s Take “More licensed operators means better patient access and more consistent product availability — both critical for maintaining therapeutic regimens. I’ve seen too many patients struggle with supply interruptions that compromise their treatment continuity.” Clinical Perspective 🧠 Patients should expect improved product availability and potentially more competitive pricing. Clinicians can anticipate fewer patient complaints about access issues and supply shortages. This expansion doesn’t change qualifying conditions or dosing considerations, but may provide patients with more product options within their therapeutic categories. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20York%20licenses%20five%20new%20medical%20marijuana%20companies%20-%20Times%20Union%20%40drcaplan&url=https%3A//www.timesunion.com/news/article/New-York-licenses-five-new-medical-marijuana-11652954.php)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.timesunion.com/news/article/New-York-licenses-five-new-medical-marijuana-11652954.php)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20York%20licenses%20five%20new%20medical%20marijuana%20companies%20-%20Times%20Union%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.timesunion.com/news/article/New-York-licenses-five-new-medical-marijuana-11652954.php)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.timesunion.com/news/article/New-York-licenses-five-new-medical-marijuana-11652954.php](https://www.timesunion.com/news/article/New-York-licenses-five-new-medical-marijuana-11652954.php) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What areas does this cannabis news cover?](#What_areas_does_this_cannabis_news_cover) - [Why is this news marked as “New”?](#Why_is_this_news_marked_as_8220New8221) - [What type of publication is this from?](#What_type_of_publication_is_this_from) - [How should healthcare providers use this information?](#How_should_healthcare_providers_use_this_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned Clinical Relevance #76 with “Notable Clinical Interest” status. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What areas does this cannabis news cover? The article covers multiple key areas including patient access, policy developments, medical cannabis applications, and patient care considerations. These topics are particularly relevant for clinicians working with cannabis therapeutics. #### Why is this news marked as “New”? The “New” designation indicates this is recent information that has been recently published or updated. Healthcare providers should be aware of these current developments in the [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) field. #### What type of publication is this from? This appears to be from CED Clinic’s cannabis news section, which focuses on clinically relevant cannabis information. The publication specializes in providing healthcare professionals with important updates in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). #### How should healthcare providers use this information? Given its “Notable Clinical Interest” rating, healthcare providers should monitor these developments closely as they may impact patient care decisions. The information appears to be particularly relevant for clinicians involved in [medical cannabis treatment](https://cedclinic.com/medical-cannabis-eligibility-book-appointment/) protocols. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [How to Start a Cannabis Business: A Complete Guide](https://cedclinic.com/cannabis-business-regulations-guide/) Learn the essential steps and regulatory considerations for launching a cannabis business in the evolving market. [Read the Guide](https://cedclinic.com/cannabis-business-regulations-guide/) Mass. Lawmakers Reach Deal on Cannabis Reform Bill – Axios Boston Discover recent legislative developments in cannabis reform that may influence other state markets. Explore the Bill ["Above and Beyond": Calls to Further Reduce Restrictions on Medicinal Cannabis Industry](https://cedclinic.com/medicinal-cannabis-licensing-calls-to-reduce-restrictions/) Insights into ongoing advocacy efforts aimed at easing medicinal cannabis regulations for better patient care. [Learn More](https://cedclinic.com/medicinal-cannabis-licensing-calls-to-reduce-restrictions/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).